Hematological Malignancies Clinical Trials

20 recruiting

Hematological Malignancies Trials at a Glance

25 actively recruiting trials for hematological malignancies are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 1 with 7 trials, with the heaviest enrollment activity in New York, Hangzhou, and Guangzhou. Lead sponsors running hematological malignancies studies include Smart Immune SAS, Children's Hospital of Fudan University, and Centre Hospitalier Régional Metz-Thionville.

Browse hematological malignancies trials by phase

Treatments under study

About Hematological Malignancies Clinical Trials

Looking for clinical trials for Hematological Malignancies? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hematological Malignancies trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hematological Malignancies clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 25 trials

Recruiting
Not Applicable

Germline Testing for Predisposition to Myeloid Malignancies

Genetic Predisposition to DiseaseMyeloid MalignancyMyeloid Hematological Malignancies
Christopher Reilly200 enrolled1 locationNCT07112287
Recruiting
Phase 2

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Hematological Malignancies
Janssen Research & Development, LLC510 enrolled78 locationsNCT04634552
Recruiting
Not Applicable

Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology

Solid TumorHematological Malignancies
Children's Hospital of Fudan University120 enrolled1 locationNCT05306509
Recruiting
Phase 1Phase 2

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

Hematological Malignancies
Daiichi Sankyo420 enrolled4 locationsNCT07220616
Recruiting

Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)

LymphomaLymphoid Hematological Malignancies
University of Zurich50 enrolled1 locationNCT07472972
Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Smoldering Multiple MyelomaMyelodysplastic SyndromesWaldenstrom Macroglobulinemia+5 more
Dana-Farber Cancer Institute10,000 enrolled7 locationsNCT02269592
Recruiting
Phase 3

Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

Hematological Malignancies
Galapagos NV546 enrolled6 locationsNCT06652633
Recruiting
Phase 2

Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation

Hematological Malignancies
University of Nebraska126 enrolled1 locationNCT06799195
Recruiting
Phase 1

A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

Hematological Malignancies
Hutchmed132 enrolled16 locationsNCT06387082
Recruiting
Phase 1

The Study of ICP-248 in Patients With Mature B-cell Malignancies

Hematological Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.191 enrolled22 locationsNCT05728658
Recruiting

18F-Pentixafor PET in Hematologic Malignancies

Hematological Malignancies
First Affiliated Hospital of Zhejiang University100 enrolled1 locationNCT07122674
Recruiting

National Longitudinal Cohort of Hematological Diseases (NICHE) - CART

Hematological Malignancies
Institute of Hematology & Blood Diseases Hospital, China1,000 enrolled1 locationNCT06607289
Recruiting

Covid-19 in Hematological Malignancies

COVID-19 Infection in Hematological Malignancies Patients
Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne3,000 enrolled6 locationsNCT04733729
Recruiting

Cord Blood Transplantation With Myeloablative Conditioning and Post-transplant Cyclophosphamide (COmPACt Study)

Hematological MalignanciesCord Blood Transplantation
Fondazione Policlinico Universitario Agostino Gemelli IRCCS10 enrolled1 locationNCT03802773
Recruiting
Not Applicable

APA and Relaxation by Biofeedback in Patients With Haematological Malignancy Admitted in ICU

AnxietyHematological MalignanciesRelaxation+1 more
Centre Hospitalier Régional Metz-Thionville90 enrolled1 locationNCT05475600
Recruiting
Not Applicable

A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging

Hematological Malignancies
Xijing Hospital120 enrolled1 locationNCT06834412
Recruiting

Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients With Hematological Malignancies and Subjected to Treatment With Immune-checkpoint Inhibitors

Hematological Malignancies
IRCCS Azienda Ospedaliero-Universitaria di Bologna100 enrolled1 locationNCT06851702
Recruiting
Phase 1

A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies

Advanced Solid TumorsHematological Malignancies
Hangzhou DAC Biotechnology Co., Ltd.110 enrolled1 locationNCT06224855
Recruiting
Not Applicable

Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies

Hematological Malignancies
University Hospital, Limoges286 enrolled4 locationsNCT06150469
Recruiting

Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies

Hematological Malignancies
University Children's Hospital, Zurich1,000 enrolled1 locationNCT06550102